selective CSF1R kinase inhibitor

oral, 30 mg BIW, phase III, cancer

from structure-based design

Molecular Cancer Therapeutics

Deciphera Pharmaceuticals

Chemical structure of molecule Vimseltinib (DCC-3014)

The Deciphera CSF1R kinase inhibitor, vimseltinib (DCC-3014), is a selective oral TKI that induces an inactive conformation of CSF1R by biomimetically nucleating an array of 17 H-bonds in the switch control…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: